US3546142A - Polyelectrolyte structures - Google Patents

Polyelectrolyte structures Download PDF

Info

Publication number
US3546142A
US3546142A US610266A US3546142DA US3546142A US 3546142 A US3546142 A US 3546142A US 610266 A US610266 A US 610266A US 3546142D A US3546142D A US 3546142DA US 3546142 A US3546142 A US 3546142A
Authority
US
United States
Prior art keywords
water
solution
weight
groups
polymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US610266A
Inventor
Alan S Michaels
Richard G Miekka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicon Corp
WR Grace and Co
Original Assignee
Amicon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicon Corp filed Critical Amicon Corp
Application granted granted Critical
Publication of US3546142A publication Critical patent/US3546142A/en
Assigned to W.R. GRACE & CO., A CORP OF CT. reassignment W.R. GRACE & CO., A CORP OF CT. MERGER (SEE DOCUMENT FOR DETAILS). EFFECTIVE 9/23/85, CONNECTICUT Assignors: AMICON CORPORATION
Assigned to W.R. GRACE & CO., A CORP. OF CT reassignment W.R. GRACE & CO., A CORP. OF CT MERGER (SEE DOCUMENT FOR DETAILS). EFFECTIVE SEPTEMBER 23, 1985. Assignors: AMICON CORPORTION, A MASS. CORP.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D67/00Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
    • B01D67/0002Organic membrane manufacture
    • B01D67/0006Organic membrane manufacture by chemical reactions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D39/00Filtering material for liquid or gaseous fluids
    • B01D39/14Other self-supporting filtering material ; Other filtering material
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D71/00Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06Organic material
    • B01D71/76Macromolecular material not specifically provided for in a single one of groups B01D71/08 - B01D71/74
    • B01D71/80Block polymers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J43/00Amphoteric ion-exchange, i.e. using ion-exchangers having cationic and anionic groups; Use of material as amphoteric ion-exchangers; Treatment of material for improving their amphoteric ion-exchange properties
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D71/00Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06Organic material
    • B01D71/30Polyalkenyl halides

Definitions

  • This invention relates to novel solid polymeric materials formed by copreciprocation of water soluble polyelectrolytes having dissociable ionic groups of opposite charge, and to methods of forming such solids.
  • the materials provided by this invention are useful as ion sorbing resins, selectively permeable and semi-permeable membranes and barriers, protective coatings, artificial biological tissues, microporous sponges and filters, semiconductor elements, and humidity sensitive conductive elements, to name but a few. They may be formed to any desired shape by casting, molding, fiber drawing, or by fabricating methods, such as machining and grinding. Thus, fibers, films, sheets, tubes, rods, and blocks of these materials may be provided and more intricate articles may be formed by casting, molding or fabricating techniques.
  • the materials of this invention are solid materials of controllable shape and dimension (as distinguished from random particles or fractured solids) formed by causing an anionic and a cationic water soluble polyelectrolyte to coprecipitate from an ion shielded solution under controlled conditions by which the shielding effect of the solution is reduced.
  • the polyelectrolytes useful in this invention are organic polymers having dissociable ionic groups which impart electrolytic characteristics in forming salts and acids (in the case of anionic polyelectrolytes) and bases (in the case at cationic polyelectrolytes).
  • Typical of these are the polymers of sodium styrene sulfonate and of vinyl benzyl trimethyl ammonium chloride, and other materials of the same general type having a synthetic organic polymeric structure, which, without the ionic groups (sulfonate or quaternary amminoum), would be a water insoluble film forming material.
  • copolymers of these materials with other vinyl compounds in molar ratios of 1:6 or less may be employed, as well as other well known polyelectrolytes of the same general type, such as polyacrylic acid, hydrolyzed copolymers of styrene and maleic anhydride, polyvinyl sulfonic acid, sulfonated polystyrene, sulfonated polyvinyl toluene, alkali metal salts of the foregoing acidic polymers, polyethyleneimine, polyvinyl pyridine, and polydimethylaminoethyl methacrylate, quaternized polyethylene imine, quaternizedpoly (dimethylaminoethyl) methacrylate, polyvinyl methyl pyridinium chloride, and the like.
  • polyacrylic acid hydrolyzed copolymers of styrene and maleic anhydride
  • polyvinyl sulfonic acid sulfon
  • polymers containing anionic groups those containing sulfonate groups are preferred, while cationic polymers containing quaternary ammonium groups are preferred, the sulfonate and quaternary ammonium groups preferably being the sole ionic groups present in the polymers.
  • This invention provides novel processes for the formation of polyelectrolyte coprecipitates into any desired shape or size, and in many instances containing widely varying relative amounts of the oppositely charged polyelectrolyte species. These formation methods are described below and apply generally to any and all solutions or mixtures containing at least one polyelectrolyte with a net anionic charge, and one polyelectrolyte with a net cationic charge which are capable of reacting ionically under proper conditions to produce solid precipitates.
  • an intimate, solvated mixture of the oppositely charged polyelectrolytes to be used (together with any desired additional fillers, plasticizing agents, etc.) is formed in a suitable solvent (usually aqueous) or solvent mixture by the addition of suflicient ionic salts, acids, and/or bases (ion shielding electrolyte) to prevent ionic interaction between the polyelectrolytes.
  • a suitable solvent usually aqueous
  • solvent mixture usually aqueous or solvent mixture by the addition of suflicient ionic salts, acids, and/or bases (ion shielding electrolyte) to prevent ionic interaction between the polyelectrolytes.
  • the mixture may be heated, and/or a suitable amount of a low polarity miscible liquid may be added as explained below to reduce the amount of ionic material required to prevent interpolymer reaction.
  • the concentration of each polyelectrolyte must be at least 0.5 percent by weight, preferably above 1.0 percent by weight of the mixture in order to
  • the salts, acids and/or bases must be present in the solution in an amount of at least 10% by weight of the total solution, preferably at least 20% by weight. Although amounts as great as 50% or more by weight of the total solution may be used, it is unnecessary and frequently undesirable to employ any more than the minimum required to prevent precipitation of the polyelectrolytes.
  • acids and bases which may be employed as ion shielding electrolytes are those which are soluble in water to the extent of at least 10% by weight at room temperature, which are highly ionized electrolytes in aqueous solution (having a pK less than 2.0), and which contain no ions which interact with the polyelectrolytes to precipitate them.
  • Such salts include the alkali metal and the alkaline earth metal salts as well as beryllium, ferrous, nickelous, cobaltous, lanthanum, manganous, stannous, and tetramethylarrimonium salts as well as alkyl pyridinium salts in which the alkyl group has from 1 to 3 carbon atoms.
  • These salts include the chlorides, bromides, nitrates and sulfates of all of the foregoing cations.
  • alkali metal chromates may be used as well as both alkali metal and alkaline earth metal perchlorates, perbromates and periodat es.
  • Acids which are useful include hydrochloric, hydrobromic, nitric, sulfuric, chromic, perchloric, perbromic, periodic, mono-, di-, and tri-chloroacetic, trifiuoroacetic, alkyl sulfonic (containing up to 20 carbon atoms in the alkyl group), and alkylbenzene sulfonic (containing up to 20 carbon atoms in the alkyl group).
  • Bases which may be used include alkali metal hydroxides, barium hydroxide, tetramethyl ammonium hydroxide, and alkylpyridinium hydroxides such as the methyl-, ethyl-, and propyl-pyridinium hydroxides.
  • any of the foregoing salts, acids or bases (shielding electrolytes) having a pK less than 2.0 in an amount of at least by weight in water will prevent the precipitation of, i.e. will maintain in solution, most of the oppositely charged polyelectrolytes described above.
  • the polyelectrolytes contain strongly ionizing groups, such as the preferred sulfonate and quaternary ammonium groups, certain of such salts, acids or bases (shielding electrolytes) are preferred for their efiectiveness and are preferably employed at elevated temperatures or in the presence of a water-miscible low polarity liquid or both.
  • the low polarity liquid is preferably an organic solvent having a volatility approximately as great as that of water or even greater.
  • Suitable solvents include acetone, dioxane, methanol, ethanol, isopropanol, tert.-butyl alcohol, pyridine, morpholine, tetrahydrofuran, N-methyl pyrrolidone, and 2-methoxy ethanol.
  • the solvent when present, may be used in amounts up to 40% by weight of the total solution, and preferably is present in an amount from 10% to 30% by weight.
  • the salts, acids or bases which are used when the polyelectrolytes contain such groups as sulfonate and quaternary ammonium are those which dissolve to the extent of at least by weight at room temperature in a mixture of water with the water-miscible volatile organic solvent when the mixture contains 50% by weight of the organic solvent.
  • the salts, acids and bases which satisfy this requirement include, among others, strong acids such as hydrochloric, hydrobromic, sulfuric, nitric, and trichloroacetic; lithium, magnesium, and calcium chlorides; alkali metal and alkaline earth metal bro- Inides; the nitrates and perchlorates of lithium and of alkaline earth metals; magnesium sulfate; and the alkali metal and alkaline earth metal salts of alkyl sulfonic acids, or aryl sulfonic acids and of alkaryl sulfonic acids in which the alkyl groups contain up to carbon atoms.
  • strong acids such as hydrochloric, hydrobromic, sulfuric, nitric, and trichloroacetic
  • lithium, magnesium, and calcium chlorides alkali metal and alkaline earth metal bro- Inides
  • the nitrates and perchlorates of lithium and of alkaline earth metals magnesium sulfate
  • solutions of those polyelectrolytes which contain such groups as sulfonate and quaternary ammonium contain in addition to water a volatile water-miscible organic solvent in an amount at least 2% by weight, or even better 10 to 30% by weight, based on the total weight of solution, and also contain at least 10% by weight (based on the total weight of solution) of a shielding electrolyte having the solubility characteristics set forth above.
  • the solution thus prepared is then caused to gel by changing conditions so as to permit at least marginal interaction to occur between the polyelectrolytes.
  • the following methods for causing initial gelation may be used:
  • the gelation step is not necessarily a distinct and separate process, but may be an integral part of the hardening process(es) described below.
  • Hardening of the mixtures gelled by any of the processes described above may be accomplished by contacting them with Water or other suitable solvent, if necessary, to extract all, or any desired portion of the residual shielding salt.
  • some polyelectrolyte systems e.g., poly(vinylbenzyltrimethyl ammonium)-poly(styrene sulfonate
  • the contractive forces developed upon extraction of the shielding salt are so great that internal porosity develops. This is prevented (if desired) by partially drying the solids after each of a series of brief washings, keeping the internal solvent composition near that at which initial gelatin occurs, until the polymer concentration becomes high enough so that internal porosity will not develop.
  • the solids may be dried as a final step in the hardening process.
  • the precipitates may be converted into any desired form by stamping, machining, sanding, carving, etc.
  • the liquid or gelled mixtures may be molded or extruded to help achieve the desired final shapes. Fibrous, particulate precipitates can be formed by adding the original liquid mixtures to water or other suitable solvent under high shear such as in a Waring Blendor.
  • the polyelectrolytes were first purified by treating aqueous solutions containing 3-5 percent by weight of the polymers with a mixture of a conventional cation exchange resin in the hydrogen form and an anionic exchange resin in the hydroxide form for about 12 hours, and the solutions were then filtered.
  • the anionic polyelectrolyte solution was then passed over a cation exchange resin in the sodium form while the other was passed over an anionic resin in the chloride form to assure that the desired counter-ions were present; the solutions were then dried.
  • Solutions Containing -10 percent by weight of each polyelectrolyte dissolved in a solvent consisting of 60 percent water, percent NaBr, and 20 percent acetone were made up with polymer equivalence ratios of 2 VBTAC/ 1 NaSS, 1 VBTAC/l NaSS, and 1 VBTAC/2 NaSS.
  • the solutions were poured into paraffin coated glass petri dishes and allowed to gel by evaporation of the acetone. The samples were next placed in an oven at 50 C.
  • an initial solution having a composition at the point designated A is brought by the elimination of acetone to a composition lying generally to the right at or near the complete shielding line.
  • gel formation occurs, and further processing is carried out to maintain the gel near the limiting composi- 6 tion for complete shielding, by removal of both water and sodium bromide until a substantially dry non-porous solid is produced.
  • sodium bromide is employed as a salt which is sufliciently soluble to provide a concentration sufficient for ionic shielding, and which is chemically inert as not to react with the polyelectrolytes.
  • Other salts having these characteristics may be employed with equally good results.
  • the presence of acetone improves the solubility of the polyelectrolytes, or, in other words, enhances the shielding effect of the sodium bromide thus rendering lower concentrations more effective.
  • EXAMPLE 2 Approximately parts by weight of pure dry, powdered poly (sodium styrene sulfonate) and 333 parts by weight of a 30 percent aqueous solution of poly (vinyl benzyl trimethyl ammonium chloride) were added with stirring to a solution containing 266 parts by weight of calcium nitrate tetrahydrate, 266 parts of dioxane, and 33 parts of water.
  • the solution so prepared was treated in the same fashion as the solution described in Example 1 above, being gelled by evaporation of the dioxane, then repeatedly dried and washed with substantially the same results.
  • membranes and filaments of polyelectrolyte coprecipitates may be prepared with or without an oriented molecular structure.
  • an oriented structure showing a high degree of birefringence under polarized light may be attained.
  • Oriented polysalt films have been obtained by drawing the initially precipitated gel 2-5 times unidirectionally, and then washing them with water and drying them.
  • a highly fibrous structure results which is similar to that of abestos.
  • Filaments have been prepared by drawing a strand from a solution of the polyelectrolytes in water acetone and NaBr slowly so as to permit gelation by acetone evaporation. After washing briefly with water, drying, and re-wetting, the filaments could be oriented by stretching 1.5-2 times their length. A 2- to 3-fold increase in the strength over the unstretched filaments results.
  • concentration of the more dilute polymer of which at least about 0.5 percent by weight is required for vinyl benzyltrimethylammonium chloride and at least about 0.2 percent by weight of sodium styrene sulfonate polymer.
  • Gels may be formed in relative ratios of 10:1 and 1:10, but compositionally stable mixtures in water are not obtained outside the ratios 5:1 and 1:5.
  • the polyelectrolyte gels of this invention exhibit semi-conductivity. When placed in a circuit between two conductors with means of reversing the polarity, the resistance in one direction was many times that of the resistance in the other direction.
  • the conductivity film is also humidity sensitive.
  • a film coated on a thumb-tack and contacted on the opposite side by a nichrome wire exhibited a resistance of 100 megohms in dry room air, but when exposed to higher humidity the resistance dropped 1000-fold in 10-15 seconds. In view 7 of this rapid response, a highly sensitive humidity sensing system is provided by this invention.
  • Shaped articles consisting essentially of a continuous gel structure having a lattice in which the sole reactants are polyelectrolytes containing sulfonate groups and those containing quaternary ammonium groups are remarkably different in properties from similar gels in which one or more of the polyelectrolytes contains weak ionic groups such as carboxylate, the former being much more moisture resistant, inter alia.
  • the method of making shaped articles of polyanionpolycation resin which comprises forming an aqueous solution containing reactive quantities of a polyanion polymer and a polycation polymer capable of coreacting to form a water-insoluble precipitate, each of said polymers being water soluble in the absence of the other, said solution containing suflicient ion shielding electrolyte at least 10% by weight of the total solution, to maintain said polymers in solution, forming the solution into the desired shape, then reducing the activity of said electrolyte until a solid gel forms.
  • the method of making shaped articles of a polyanionpolycation resin which comprises dissolving reactive quantities of poly (sodium styrene sulfonate) and poly (vinyl benzyl trimethyl ammonium chloride) in a solvent comprising water, acetone and sodium bromide in an amount sufiicient to maintain a solution, said sodium bromide being present in an amount of at least 10% by weight of the total solution, then causing the acetone to evaporate from said solution until a solid gel forms.
  • the method of making shaped articles of polyanionpolycation resin which comprises forming an aqueous solution containing reactive quantities of two synthetic organic polymers, one of said polymers having dissociable anionic sulfonate groups attached to a polymeric chain which without the said anionic groups forms a water-insoluble film-forming resin, the other of said polymers having dissociable cationic quaternary ammonium groups attached to a polymeric chain which without said cationic groups forms a water-insoluble film-forming resin, each of said polymers having suflicient dissociable groups to render it water soluble in the absence of the other, said solution containing at least 2% by weight of a volatile water-miscible organic solvent and at least 10% by weight of an electrolyte having a pK less than 2.0 which is soluble to the extent of at least 15% by weight at room temperature in a mixture of Water with 50% by weight of said organic solvent, forming the solution into the desired shape, then reducing the activity of said electrolyte by cooling the solution until
  • the method of making shaped articles of polyanionpolycation resin which comprises forming an aqueous solution containing reactive quantities of two synthetic organic polymers, one of said polymers having dissociable anionic sulfonate groups attached to a polymeric chain which without the said anionic groups forms a water-insoluble film-forming resin, the other of said polymers having dissociable cationic quaternary ammonium groups attached to a polymeric chain which without said cationic groups forms a water-insoluble film-forming resin, each of said polymers having sufiicient dissociable groups to render it water soluble in the absence of the other, said solution containing at least 2% by weight of a volatile water-miscible organic solvent and at least 10% by weight of a volatile electrolyte having a pK less than 2.0 which is soluble to the extent of at least 15% by weight at room temperature in a mixture of water with 50% by weight of said organic solvent, forming the solution into the desired shape, then reducing the activity of said electrolyte by
  • the method of making shaped articles of polyanion-polycation resin which comprises forming an aqueous solution containing reactive quantities of two synthetic organic polymers, one of said polymers having dissociable anionic sulfonate groups attached to a polymeric chain which without the said anionic groups forms a water-insoluble film-forming resin, the other of said polymers having dissociable cationic quaternary ammonium groups attached to a polymeric chain which without said cationic groups forms a water-insoluble resin, each of said polymers having sufficient dissociable groups to render it water soluble in the absence of the other, said solution containing at least 2% by weight of a volatile water-miscible organic solvent and at least 10% by weight of an acid having a pK less than 2.0 which is soluble to the extent of at least 15% by weight at room temperature in a mixture of water with 50% by weight of said organic solvent, forming the solution into the desired shape, then reducing the activity of said acid by neutralization thereof until a solid gel forms.
  • the method of making shaped articles of polyanion-polycation resin which comprises forming an aqueous solution containing reactive quantities of two synthetic organic polymers, one of said polymers having dissociable anionic sulfonate groups attached to a polymeric chain which without the said anionic groups forms a water-insoluble film-forming resin, the other of said polymers having dissociable cationic quaternary ammonium groups attached to a polymeric chain which without said cationic groups form a waterinsoluble film-forming resin, each of said polymers having sufficient dissociable groups to render it water soluble in the absence of the other, said solution extent of at least 15% by weight at room temperature in solvent, forming the solution into the desired shape, then anion-polycation resin which comprises forming an aquewhich is soluble to the extent of at least 15% by weight at room temperature in a mixture of water with 50% by weight of said organic solvent, forming the solution into the desired shape, then reducing the activity of said base by neutralization thereof until a solid gel forms.
  • said polymers are the sole polymers present in said solution and said polyanion polymer contains dissociable sulfonate groups attached to a polymeric chain which without the said sulfonate groups forms a water-insoluble film-forming resin, said sulfonate groups being the sole ionic groups present in said polyanion polymer, wherein said polycation polymer contains dissociable quaternary ammonium groups attached to a polymeric chain which without the said quaternary ammonium groups forms a water-insoluble film-forming resin, said quaternary ammonium groups being the sole ionic groups present in said polycation polymer, and wherein said solution contains in addition a water-miscible organic solvent.

Description

a, 19mm A, s. gt-m ps ETAL 3,546,142 I r onmmcwnom'm STRUCTURES v v and Ja 19. 196'! United States Patent 3,546,142 POLYELECTROLYTE STRUCTURES Alan S. Michaels, Lexington, and Richard G. Miekka, East Natick, Mass., assignors to Amicon Corporation, Cambridge, Mass., a corporation of Massachusetts Continuation-impart of application Ser. No. 341,834, Jan. 24, 1964, which is a continuation-in-part of application Ser. No. 147,320, Oct. 24, 1961. This application Jan. 19, 1967, Ser. No. 610,266
Int. Cl. C08f 27/06 US. Cl. 260-21 21 Claims ABSTRACT OF THE DISCLOSURE Dissolving a polycation polymer and a polyanion polymer in a mixture of water and electrolyte and optionally a water-miscible organic solvent, forming the solution into the desired shape, and reducing the activity of the electrolyte until a gel forms. The activity of the solution is reduced by dilution or cooling or removing electrolyte or evaporating solvent. The electrolyte may be volatile and removed by evaporation, or it may be acidic or basic, and its activity may be reduced by neutralization. The shaped articles are useful as ion sorbing resins, selectively permeable and semi-permeable membranes, protective coatings, artificial biological tissues, microporous sponges and filters, semi-conductor elements, and humidity sensitive conductive elements.
This application is a continuation-in-part of application Ser. No. 341,834 filed Jan. 24, 1964, now abandoned, which in turn is a continuation-in-part of application Ser. No. 147,320 filed Oct. 24, 1961 also now abandoned.
This invention relates to novel solid polymeric materials formed by copreciprocation of water soluble polyelectrolytes having dissociable ionic groups of opposite charge, and to methods of forming such solids. The materials provided by this invention are useful as ion sorbing resins, selectively permeable and semi-permeable membranes and barriers, protective coatings, artificial biological tissues, microporous sponges and filters, semiconductor elements, and humidity sensitive conductive elements, to name but a few. They may be formed to any desired shape by casting, molding, fiber drawing, or by fabricating methods, such as machining and grinding. Thus, fibers, films, sheets, tubes, rods, and blocks of these materials may be provided and more intricate articles may be formed by casting, molding or fabricating techniques.
In general, the materials of this invention are solid materials of controllable shape and dimension (as distinguished from random particles or fractured solids) formed by causing an anionic and a cationic water soluble polyelectrolyte to coprecipitate from an ion shielded solution under controlled conditions by which the shielding effect of the solution is reduced.
The polyelectrolytes useful in this invention are organic polymers having dissociable ionic groups which impart electrolytic characteristics in forming salts and acids (in the case of anionic polyelectrolytes) and bases (in the case at cationic polyelectrolytes). Typical of these are the polymers of sodium styrene sulfonate and of vinyl benzyl trimethyl ammonium chloride, and other materials of the same general type having a synthetic organic polymeric structure, which, without the ionic groups (sulfonate or quaternary amminoum), would be a water insoluble film forming material. They are accordingly chracterized by a sufficiently high molecular weight to be solid and capable of film formation (typically greater than 50,000) while having sufiicient dissociable ionic groups chemically bonded to the polmeric structure to be water soluble. As a very general rule there should be at least one ionic group for every six repeating monomer (mer) units, or for each average chain interval of 12 carbon atoms.
Thus, in addition to the preferred polymers of sodium styrene sulfonate and vinyl benzyl trimethyl ammonium chloride, copolymers of these materials with other vinyl compounds in molar ratios of 1:6 or less may be employed, as well as other well known polyelectrolytes of the same general type, such as polyacrylic acid, hydrolyzed copolymers of styrene and maleic anhydride, polyvinyl sulfonic acid, sulfonated polystyrene, sulfonated polyvinyl toluene, alkali metal salts of the foregoing acidic polymers, polyethyleneimine, polyvinyl pyridine, and polydimethylaminoethyl methacrylate, quaternized polyethylene imine, quaternizedpoly (dimethylaminoethyl) methacrylate, polyvinyl methyl pyridinium chloride, and the like. Of the polymers containing anionic groups, those containing sulfonate groups are preferred, while cationic polymers containing quaternary ammonium groups are preferred, the sulfonate and quaternary ammonium groups preferably being the sole ionic groups present in the polymers.
When solutions of oppositely charged polyelectrolytes are mixed together under proper conditions of concentration and temperature, the oppositely charged macroions coreact ionically and precipitate from solution. Because of their high charge density, polyelectrolytes have a much greater tendency to associate with each other than do their corresponding monomers. Most polyelectrolyte precipitates can be dissolved, or their formation prevented, by the addition of sufi'icient amounts of inditferent soluble ionic salts such as magnesium sulfate or sodium chloride. Subsequent removal or dilution of these shielding salts results in reprecipitation of the polyelectrolyte complexes.
This invention provides novel processes for the formation of polyelectrolyte coprecipitates into any desired shape or size, and in many instances containing widely varying relative amounts of the oppositely charged polyelectrolyte species. These formation methods are described below and apply generally to any and all solutions or mixtures containing at least one polyelectrolyte with a net anionic charge, and one polyelectrolyte with a net cationic charge which are capable of reacting ionically under proper conditions to produce solid precipitates.
In practicing the method of this invention, an intimate, solvated mixture of the oppositely charged polyelectrolytes to be used (together with any desired additional fillers, plasticizing agents, etc.) is formed in a suitable solvent (usually aqueous) or solvent mixture by the addition of suflicient ionic salts, acids, and/or bases (ion shielding electrolyte) to prevent ionic interaction between the polyelectrolytes. The mixture may be heated, and/or a suitable amount of a low polarity miscible liquid may be added as explained below to reduce the amount of ionic material required to prevent interpolymer reaction. In general, the concentration of each polyelectrolyte must be at least 0.5 percent by weight, preferably above 1.0 percent by weight of the mixture in order to obtain continuous solids in the subsequent processing.
The salts, acids and/or bases must be present in the solution in an amount of at least 10% by weight of the total solution, preferably at least 20% by weight. Although amounts as great as 50% or more by weight of the total solution may be used, it is unnecessary and frequently undesirable to employ any more than the minimum required to prevent precipitation of the polyelectrolytes. Among the salts, acids and bases which may be employed as ion shielding electrolytes are those which are soluble in water to the extent of at least 10% by weight at room temperature, which are highly ionized electrolytes in aqueous solution (having a pK less than 2.0), and which contain no ions which interact with the polyelectrolytes to precipitate them. Such salts include the alkali metal and the alkaline earth metal salts as well as beryllium, ferrous, nickelous, cobaltous, lanthanum, manganous, stannous, and tetramethylarrimonium salts as well as alkyl pyridinium salts in which the alkyl group has from 1 to 3 carbon atoms. These salts include the chlorides, bromides, nitrates and sulfates of all of the foregoing cations. In addition, alkali metal chromates may be used as well as both alkali metal and alkaline earth metal perchlorates, perbromates and periodat es. Acids which are useful include hydrochloric, hydrobromic, nitric, sulfuric, chromic, perchloric, perbromic, periodic, mono-, di-, and tri-chloroacetic, trifiuoroacetic, alkyl sulfonic (containing up to 20 carbon atoms in the alkyl group), and alkylbenzene sulfonic (containing up to 20 carbon atoms in the alkyl group). Bases which may be used include alkali metal hydroxides, barium hydroxide, tetramethyl ammonium hydroxide, and alkylpyridinium hydroxides such as the methyl-, ethyl-, and propyl-pyridinium hydroxides.
The presence of any of the foregoing salts, acids or bases (shielding electrolytes) having a pK less than 2.0 in an amount of at least by weight in water will prevent the precipitation of, i.e. will maintain in solution, most of the oppositely charged polyelectrolytes described above. However, when the polyelectrolytes contain strongly ionizing groups, such as the preferred sulfonate and quaternary ammonium groups, certain of such salts, acids or bases (shielding electrolytes) are preferred for their efiectiveness and are preferably employed at elevated temperatures or in the presence of a water-miscible low polarity liquid or both.
The low polarity liquid is preferably an organic solvent having a volatility approximately as great as that of water or even greater. Suitable solvents include acetone, dioxane, methanol, ethanol, isopropanol, tert.-butyl alcohol, pyridine, morpholine, tetrahydrofuran, N-methyl pyrrolidone, and 2-methoxy ethanol. The solvent, when present, may be used in amounts up to 40% by weight of the total solution, and preferably is present in an amount from 10% to 30% by weight.
The salts, acids or bases (shielding electrolytes) which are used when the polyelectrolytes contain such groups as sulfonate and quaternary ammonium are those which dissolve to the extent of at least by weight at room temperature in a mixture of water with the water-miscible volatile organic solvent when the mixture contains 50% by weight of the organic solvent. The salts, acids and bases which satisfy this requirement include, among others, strong acids such as hydrochloric, hydrobromic, sulfuric, nitric, and trichloroacetic; lithium, magnesium, and calcium chlorides; alkali metal and alkaline earth metal bro- Inides; the nitrates and perchlorates of lithium and of alkaline earth metals; magnesium sulfate; and the alkali metal and alkaline earth metal salts of alkyl sulfonic acids, or aryl sulfonic acids and of alkaryl sulfonic acids in which the alkyl groups contain up to carbon atoms. Preferably solutions of those polyelectrolytes which contain such groups as sulfonate and quaternary ammonium contain in addition to water a volatile water-miscible organic solvent in an amount at least 2% by weight, or even better 10 to 30% by weight, based on the total weight of solution, and also contain at least 10% by weight (based on the total weight of solution) of a shielding electrolyte having the solubility characteristics set forth above.
The solution thus prepared is then caused to gel by changing conditions so as to permit at least marginal interaction to occur between the polyelectrolytes. The following methods for causing initial gelation may be used:
(a) By cooling a mixture which contains only enough salt, acid, and/or base to prevent interpolymer reaction at elevated temperatures. The method is ideally suited for applying uniform coatings to objects of almost any shape by the simple expedient of dipping the cooled object into a hot, marginally shielded polyelectrolyte mixture until a layer of gelled mixture of the desired thickness has built up on the surface of the object.
(b) By evaporation of a volatile liquid component from a mixture to which a volatile, low polarity liquid (e.g. acetone) has been added to reduce the amount of salt required to shield the polyions. We have found that this technique of gelation is particularly useful for the formation of fibers or filaments of polyelectrolyte coprecipitates: If a rod or other solid object is dipped into such a mixture and slowly removed, a monofilament of the mixture is drawn out which gels rapidly by solvent-evaporation. Filaments of indefinite length, and very uniform diameter can be prepared in this fashion. Alternatively, the solution can be extruded through a die in the form of filaments into warm air, where gelation rapidly takes place. These filaments can then be washed, stretched, dried, or otherwise treated to convert them into strong, resilient fibers,
(c) By reducing the concentration of the shielding ionic species. This may be accomplished by evaporating a volatile electrolyte, by diluting the mixtures, or contacting their surfaces with water or other suitable solvent to extract the microions. Rapid surface gelation prevents the loss of polymer into the extracting solution but permits water soluble impurities such as salts, etc., to be removed.
(d) By neutralization of shielding acids or bases. Polyelectrolytes whose ionic functions are carboxyl or amine groups are usually more easily shielded by strong acids or bases than by ordinary salts. Raising the pH (acidshielded systems), or lowering the pH (base-shielded systems) will result in gelation provided the amount of salt produced in the neutralization reaction is insufficient to prevent interpolymer reaction.
All of the foregoing changes in conditions involve a reduction in the activity of the electrolyte, and the term reducing the activity of the electrolyte is a generic term which embraces all of these operations.
It should be noted that the gelation step is not necessarily a distinct and separate process, but may be an integral part of the hardening process(es) described below.
Hardening of the mixtures gelled by any of the processes described above may be accomplished by contacting them with Water or other suitable solvent, if necessary, to extract all, or any desired portion of the residual shielding salt. With some polyelectrolyte systems (e.g., poly(vinylbenzyltrimethyl ammonium)-poly(styrene sulfonate) the contractive forces developed upon extraction of the shielding salt are so great that internal porosity develops. This is prevented (if desired) by partially drying the solids after each of a series of brief washings, keeping the internal solvent composition near that at which initial gelatin occurs, until the polymer concentration becomes high enough so that internal porosity will not develop. The solids may be dried as a final step in the hardening process.
After hardening, the precipitates may be converted into any desired form by stamping, machining, sanding, carving, etc. Before hardening, the liquid or gelled mixtures may be molded or extruded to help achieve the desired final shapes. Fibrous, particulate precipitates can be formed by adding the original liquid mixtures to water or other suitable solvent under high shear such as in a Waring Blendor.
A preferred method of carrying out this invention is described in detail below with reference to the formation of a coprecipitate of poly (sodium styrene sulfonate) and poly (vinyl benzyl trimethyl ammonium chloride) from a solvent mixture of water, acetone, and sodium bromide. Reference is made to the accompanying drawing which is a ternary diagram showing the solubility of the polyelectrolytes in the water-acetone-sodium bromide system.
EXAMPLE 1 In this procedure poly (sodium styrene sulfonate), (NaSS) an anionic polyelectrolyte having an average molecular weight of about 760,000, and poly (vinyl benzyl trimethyl ammonium chloride), (VBTAC) a cationic polyelectrolyte having an average molecular Weight of about 300,000, were reacted together to yield transparent solid resins of controlled shape and size. The polyelectrolytes were first purified by treating aqueous solutions containing 3-5 percent by weight of the polymers with a mixture of a conventional cation exchange resin in the hydrogen form and an anionic exchange resin in the hydroxide form for about 12 hours, and the solutions were then filtered. The anionic polyelectrolyte solution was then passed over a cation exchange resin in the sodium form while the other was passed over an anionic resin in the chloride form to assure that the desired counter-ions were present; the solutions were then dried.
Solutions Containing -10 percent by weight of each polyelectrolyte dissolved in a solvent consisting of 60 percent water, percent NaBr, and 20 percent acetone were made up with polymer equivalence ratios of 2 VBTAC/ 1 NaSS, 1 VBTAC/l NaSS, and 1 VBTAC/2 NaSS. The solutions were poured into paraffin coated glass petri dishes and allowed to gel by evaporation of the acetone. The samples were next placed in an oven at 50 C. to evaporate water until, or shortly before, a slight opacity developed at the periphery of the gels due to salt out of NaSS, and were then washed briefly with water to extract some of the NaBr, and replaced in the oven to again allow water evaporation to the point of insipient NaSS precipitation. This alternate washing and drying procedure was continued until the polymer content was 40-50 percent of the total weight of the samples, after which the polysalts were washed with demineralized water until no more salt could be extracted from them, cut into samples of the desired size, and dried at 50 percent humidity over a sulfuric acid-water mixture to yield amber, transparent solids. The purpose of this rather elaborate wash-dry procedure was to remove as much salt, water, and acetone as possible from the polysalts While keeping the overall solvent composition near the region of polysalt solubility. If too much salt was extracted from the dilute gels by prolonged contact with water, internal porosity developed due to contraction of the polymer volume, and the final polysalts were microporous sponges rather than ,continuous solids. Where a porous structure is desired, drying is carried out without the intermediate washing steps.
After final washing of the polysalts, the interpolymer reactions were found to be surprisingly complete. No sodium could be detected by flame tests made on samples cut from the quaternary-rich polysalts, and no visible silver halide precipitate was formed when silver nitrate solution was added to a tenth molar sodium nitrate solution which had been equilibrated with a sample of NaSS-rich polysalt. The neutral polysalts gave negative tests for both sodium and bromide ions, with the exception that small opaque regions (if present) at the periphery of the samples gave weak positive flame tests for sodium. I
The mechanism of gel formation demonstrated in the preceding example is readily understood by referring to the ternary diagram given in the drawing. The presence of sodium bromide in sufiicient concentration has a shielding effect which prevents the two polyelectrolytes from reacting, while the presence of acetone reduces the amount of sodium bromide required, as shown by curve designated complete shielding. Above and to the left of this curve the polyelectrolytes remain in solution, while at compositions below and to the right of this curve, precipitation occurs. It will also be noted that at relatively high acetone concentrations and/or sodium bromide concentrations a second limiting effect arises from the anionic polyelectrolyte being salted out separatedly from the cationic polyelectrolyte.
In the foregoing example an initial solution having a composition at the point designated A is brought by the elimination of acetone to a composition lying generally to the right at or near the complete shielding line. At this point gel formation occurs, and further processing is carried out to maintain the gel near the limiting composi- 6 tion for complete shielding, by removal of both water and sodium bromide until a substantially dry non-porous solid is produced.
In the ternary solvent system, sodium bromide is employed as a salt which is sufliciently soluble to provide a concentration sufficient for ionic shielding, and which is chemically inert as not to react with the polyelectrolytes. Other salts having these characteristics may be employed with equally good results. The presence of acetone improves the solubility of the polyelectrolytes, or, in other words, enhances the shielding effect of the sodium bromide thus rendering lower concentrations more effective. Other water-miscible volatile organic solvents particularly those which are solvent for the organic polymer structure itself (without the ionic groups) may be used instead with similar results, or alternatively the organic solvent fraction may be omitted altogether, par ticularly where the polyelectrolytes do not contain strong ionic groups such as sulfonate or quaternary ammonium groups, or where the solution is cooled from an elevated temperature to effect coprecipitation.
EXAMPLE 2 Approximately parts by weight of pure dry, powdered poly (sodium styrene sulfonate) and 333 parts by weight of a 30 percent aqueous solution of poly (vinyl benzyl trimethyl ammonium chloride) were added with stirring to a solution containing 266 parts by weight of calcium nitrate tetrahydrate, 266 parts of dioxane, and 33 parts of water.
The solution so prepared was treated in the same fashion as the solution described in Example 1 above, being gelled by evaporation of the dioxane, then repeatedly dried and washed with substantially the same results.
Equally good results may be obtained by substituting other salts, acids or bases, and other organic solvents, as set forth hereinabove, for those in Examples 1 and 2.
In addition to massive gel structures, membranes and filaments of polyelectrolyte coprecipitates may be prepared with or without an oriented molecular structure. By stretching the membrane or filament, an oriented structure showing a high degree of birefringence under polarized light may be attained. Oriented polysalt films have been obtained by drawing the initially precipitated gel 2-5 times unidirectionally, and then washing them with water and drying them. A highly fibrous structure results which is similar to that of abestos. Filaments have been prepared by drawing a strand from a solution of the polyelectrolytes in water acetone and NaBr slowly so as to permit gelation by acetone evaporation. After washing briefly with water, drying, and re-wetting, the filaments could be oriented by stretching 1.5-2 times their length. A 2- to 3-fold increase in the strength over the unstretched filaments results.
The ability of ion shielded polyelectrolyte solutions to gel has been found not to be dependent on the relative amounts of the two polymers in solution, at least up to a ratio of 30:1 of one polyelectrolyte over the other. The
important variable is the concentration of the more dilute polymer, of which at least about 0.5 percent by weight is required for vinyl benzyltrimethylammonium chloride and at least about 0.2 percent by weight of sodium styrene sulfonate polymer. Gels may be formed in relative ratios of 10:1 and 1:10, but compositionally stable mixtures in water are not obtained outside the ratios 5:1 and 1:5.
In electrical circuits the polyelectrolyte gels of this invention exhibit semi-conductivity. When placed in a circuit between two conductors with means of reversing the polarity, the resistance in one direction was many times that of the resistance in the other direction. The conductivity film is also humidity sensitive. A film coated on a thumb-tack and contacted on the opposite side by a nichrome wire exhibited a resistance of 100 megohms in dry room air, but when exposed to higher humidity the resistance dropped 1000-fold in 10-15 seconds. In view 7 of this rapid response, a highly sensitive humidity sensing system is provided by this invention.
Shaped articles consisting essentially of a continuous gel structure having a lattice in which the sole reactants are polyelectrolytes containing sulfonate groups and those containing quaternary ammonium groups are remarkably different in properties from similar gels in which one or more of the polyelectrolytes contains weak ionic groups such as carboxylate, the former being much more moisture resistant, inter alia.
From the foregoing disclosure it will be seen that a novel type of polymeric material having a great variety of uses and applications is available. Although the invention has been described with specific reference to its presently preferred embodiment, it is contemplated that modifications will readily occur to those skilled in the art and familiar with this disclosure and that such can be made without departing from the scope of this invention. In particular it is contemplated that those skilled in the art will readily select other polyelectrolytes and solvent systems for them by which the general technique of precipitation from an ion shielded solution described herein may be employed.
Having thus disclosed our invention, we claim and desire to secure by Letters Patent:
1. The method of making shaped articles of polyanionpolycation resin which comprises forming an aqueous solution containing reactive quantities of a polyanion polymer and a polycation polymer capable of coreacting to form a water-insoluble precipitate, each of said polymers being water soluble in the absence of the other, said solution containing suflicient ion shielding electrolyte at least 10% by weight of the total solution, to maintain said polymers in solution, forming the solution into the desired shape, then reducing the activity of said electrolyte until a solid gel forms.
2. The method of claim 1 wherein the activity of the electrolyte is reduced by diluting the solution to lower the electrolyte concentration.
3. The method of claim 1 wherein the activity of the electrolyte is reduced by cooling the solution.
4. The method of claim 1 wherein the activity of the electrolyte is reduced by removing electrolyte from the solution.
5. The method of claim 1 wherein the solution contains in addition a water-miscible organic solvent and wherein the activity of the electrolyte is reduced by evaporating said solvent from the solution.
6. The method of claim 1 wherein the solution contains in addition a water-miscible organic solvent and wherein the activity of the electrolyte is reduced by diluting the solution with water to lower the electrolyte concentration.
7. The method of claim 1 wherein the solution contains in addition a water-miscible organic solvent and wherein the activity of the electrolyte is reduced by cooling the solution.
8. The method of claim 1 wherein the solution contains in addition a water-miscible organic solvent and wherein the activity of the electrolyte is reduced by removing electrolyte from the solution.
9. The method of claim 1 wherein the electrolyte is an acid and its activity is reduced by neutralization.
10. The method of claim 1 wherenin the electrolyte is a base and its activity is reduced by neutralization.
11. The method of claim 9 wherein the solution contains in addition a water-miscible organic solvent.
12. The method of claim 10 wherein the solution contains in addition a water-miscible organic solvent.
13. The method of making shaped articles of a polyanionpolycation resin which comprises dissolving reactive quantities of poly (sodium styrene sulfonate) and poly (vinyl benzyl trimethyl ammonium chloride) in a solvent comprising water, acetone and sodium bromide in an amount sufiicient to maintain a solution, said sodium bromide being present in an amount of at least 10% by weight of the total solution, then causing the acetone to evaporate from said solution until a solid gel forms.
14. The method of making shaped articles of polyanionpolycation resin which comprises forming an aqueous solution containing reactive quantities of two synthetic organic polymers, one of said polymers having dissociable anionic sulfonate groups attached to a polymeric chain which without the said anionic groups forms a water-insoluble film-forming resin, the other of said polymers having dissociable cationic quaternary ammonium groups attached to a polymeric chain which without said cationic groups forms a water-insoluble film-forming resin, each of said polymers having suflicient dissociable groups to render it water soluble in the absence of the other, said solution containing at least 2% by weight of a volatile water-miscible organic solvent and at least 10% by weight of an electrolyte having a pK less than 2.0 which is soluble to the extent of at least 15% by weight at room temperature in a mixture of Water with 50% by weight of said organic solvent, forming the solution into the desired shape, then reducing the activity of said electrolyte by cooling the solution until a solid gel forms.
15. The method of making shaped articles of polyanionpolycation resin which comprises forming an aqueous solution containing reactive quantities of two synthetic organic polymers, one of said polymers having dissociable anionic sulfonate groups attached to a polymeric chain which without the said anionic groups forms a water-insoluble film-forming resin, the other of said polymers having dissociable cationic quaternary ammonium groups attached to a polymeric chain which without said cationic groups forms a water-insoluble film-forming resin, each of said polymers having sufiicient dissociable groups to render it water soluble in the absence of the other, said solution containing at least 2% by weight of a volatile water-miscible organic solvent and at least 10% by weight of a volatile electrolyte having a pK less than 2.0 which is soluble to the extent of at least 15% by weight at room temperature in a mixture of water with 50% by weight of said organic solvent, forming the solution into the desired shape, then reducing the activity of said electrolyte by evaporating it from the solution until a solid gel forms.
16. The method of making shaped articles of polyanion-polycation resin which comprises forming an aqueous solution containing reactive quantities of two synthetic organic polymers, one of said polymers having dissociable anionic sulfonate groups attached to a polymeric chain which without the said anionic groups forms a water-insoluble film-forming resin, the other of said polymers having dissociable cationic quaternary ammonium groups attached to a polymeric chain which without said cationic groups forms a water-insoluble resin, each of said polymers having sufficient dissociable groups to render it water soluble in the absence of the other, said solution containing at least 2% by weight of a volatile water-miscible organic solvent and at least 10% by weight of an acid having a pK less than 2.0 which is soluble to the extent of at least 15% by weight at room temperature in a mixture of water with 50% by weight of said organic solvent, forming the solution into the desired shape, then reducing the activity of said acid by neutralization thereof until a solid gel forms.
17. The method of making shaped articles of polyanion-polycation resin which comprises forming an aqueous solution containing reactive quantities of two synthetic organic polymers, one of said polymers having dissociable anionic sulfonate groups attached to a polymeric chain which without the said anionic groups forms a water-insoluble film-forming resin, the other of said polymers having dissociable cationic quaternary ammonium groups attached to a polymeric chain which without said cationic groups form a waterinsoluble film-forming resin, each of said polymers having sufficient dissociable groups to render it water soluble in the absence of the other, said solution extent of at least 15% by weight at room temperature in solvent, forming the solution into the desired shape, then anion-polycation resin which comprises forming an aquewhich is soluble to the extent of at least 15% by weight at room temperature in a mixture of water with 50% by weight of said organic solvent, forming the solution into the desired shape, then reducing the activity of said base by neutralization thereof until a solid gel forms.
18. The method of claim 1 wherein said polymers are the sole polymers present in said solution and said polyanion polymer contains dissociable sulfonate groups attached to a polymeric chain which without the said sulfonate groups forms a water-insoluble film-forming resin, said sulfonate groups being the sole ionic groups present in said polyanion polymer, wherein said polycation polymer contains dissociable quaternary ammonium groups attached to a polymeric chain which without the said quaternary ammonium groups forms a water-insoluble film-forming resin, said quaternary ammonium groups being the sole ionic groups present in said polycation polymer, and wherein said solution contains in addition a water-miscible organic solvent.
19. A stable aqueous solution containing a synthetic organic polymer having dissociable anionic groups attached to a polymeric chain which without said anionic groups forms a water insoluble film-forming resin, and a second synthetic organic polymer having dissociable cationic groups attached to a polymeric chain which without said cationic groups forms a water insoluble film-forming resin, each of the polymers having suflicient dissociable groups to render it water-soluble in the absence of the other, at least 10% by weight, based on the total weight of solution, of an electrolyte having a pK less than 2.0, and a water-miscible organic solvent.
20. A stable aqueous solution as claimed in claim 19 in which said anionic groups are sulfonate groups and said cationic groups are quaternary ammonium groups.
21. A stable aqueous solution as claimed in claim 19 in which one of said polymers is poly (sodium styrene sulfonate) and the other is poly (vinyl benzyl trimethyl ammonium chloride).
References Cited UNITED STATES PATENTS 2,832,746 4/1958 Jackson 2602.1 2,832,747 4/1958 Jackson 260-2.1 3,041,292 6/1962 Hatch 260-21 HAROLD D. ANDERSON, Primary Examiner (5/69) UNKTED STATEb- PATENT OFFICE CERTIFICATE OF. CORRECTION Patent No. 3 5 4 b l'fl 2 Dated December 5 1970 Inventor-(s) Alan S. Michaels anci Richard G Miekka It is certified that: error appears in the above id entified at and that said Letters Patent: are hereby corrected as shown below em:
Column 1-, line 36, "copreeipitation is misspelled;
Column 1, line- 51, "dimension" should be c i imensions-;
Colu mn 1, line "ammonium" misspelled;
col mnj in n, "'p fl ymel-c'? is-"misspelled;
po umrg' '2,: li ne 1 5,
Col n inn 8, line 7Q, "Tome" should f be Columnl l'iri'esfg -to are typeduinoorieotly end is i tjygedfb-elow a'sufollPfg-s:
vgjgtqeJew-mi,sciblge op'g a nicj solveritya ndjfatf leesp- 1O%'= pyhwe'ight of a haste-having 'epli--less. thsf;..-.2.. Q "which is solublef-"bofgfihej extent of at -l -.e-as t 15% jlkmkainin at leia'. s -t '2 j%" ;oy'i weight" 611 ibis tile .I by weight" -a t-' "roo mf-temperature in -.e.. mi' Xt-ure of water with 50% byweigh t'iipffsaid organ icflsolx'renp', forming "the so'l-ption .1ntjf1;ne desire-d shapegflthn reducing t'h'eleojtivity off said base by; neutralization thereof si ned and sea-e di-fmiez'nd dayq ualte rni zedpo15H :is hould be two words
US610266A 1967-01-19 1967-01-19 Polyelectrolyte structures Expired - Lifetime US3546142A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61026667A 1967-01-19 1967-01-19

Publications (1)

Publication Number Publication Date
US3546142A true US3546142A (en) 1970-12-08

Family

ID=24444354

Family Applications (1)

Application Number Title Priority Date Filing Date
US610266A Expired - Lifetime US3546142A (en) 1967-01-19 1967-01-19 Polyelectrolyte structures

Country Status (1)

Country Link
US (1) US3546142A (en)

Cited By (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737045A (en) * 1969-12-20 1973-06-05 Uivac Corp Membrane for use in dialysis and ultrafiltration and the production of such member
US3993616A (en) * 1974-08-05 1976-11-23 The Dow Chemical Company Alkali metal carboxylic polyelectrolyte solutions with N-methylol crosslinker
US3996318A (en) * 1972-12-21 1976-12-07 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Ten Behoeve Van Nijverheid, Handel En Verkeer Dynamic membrane
JPS5334887A (en) * 1971-07-02 1978-03-31 Rhone Poulenc Sa Process for preparing ionncrosslinked polymer
US4116545A (en) * 1976-10-27 1978-09-26 American Cyanamid Company Polymeric electrolyte for electrochromic display devices
FR2418252A1 (en) * 1978-02-27 1979-09-21 Ici Australia Ltd PROCESS FOR THE PRODUCTION OF AN AMPHOTERE RESIN OF IONIC EXCHANGE AND RESIN OBTAINED
US4377481A (en) * 1980-11-14 1983-03-22 Abcor, Inc. Blended, polymeric, matrix membrane and process of making and using same
US4439322A (en) * 1980-07-02 1984-03-27 Toray Industries, Inc. Polymethyl methacrylate membrane
US4489180A (en) * 1983-12-12 1984-12-18 Exxon Research And Engineering Co. Drag reduction agent utilizing water soluble interpolymer complexes
US4511677A (en) * 1983-11-02 1985-04-16 Phillips Petroleum Company Ion exchange-active compositions consisting of water-soluble polyelectrolyte upon ion exchange functional substrate
US4511473A (en) * 1982-02-09 1985-04-16 Amf Incorporated Fibrous media containing millimicron-sized particulates
US4516982A (en) * 1983-11-02 1985-05-14 Exxon Research And Engineering Co. Antimisting system for hydrocarbon fluids
US4517333A (en) * 1983-12-12 1985-05-14 Exxon Research And Engineering Co. Novel viscosifiers for aqueous fluids based on polymer complexes
US4536539A (en) * 1983-12-12 1985-08-20 Exxon Research And Engineering Co. Dilatant behavior of interpolymer complexes in aqueous solution
US4539373A (en) * 1982-07-12 1985-09-03 The Dow Chemical Company Thermoplastic polyelectrolyte complexes
US4665115A (en) * 1984-08-22 1987-05-12 Exxon Research And Engineering Company Method for controlling viscosity of organic liquids and compositions
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US4704324A (en) * 1985-04-03 1987-11-03 The Dow Chemical Company Semi-permeable membranes prepared via reaction of cationic groups with nucleophilic groups
US4737534A (en) * 1983-11-02 1988-04-12 Exxon Research And Engineering Company Method for controlling viscosity of organic liquids and compositions thereof
EP0285563A1 (en) 1987-04-02 1988-10-05 Ciba-Geigy Ag Transdermal therapeutic systems for combinations of active agents
US4839203A (en) * 1985-04-03 1989-06-13 The Dow Chemical Company Semi-permeable membranes prepared via reaction of cationic groups with nucleophilic groups
US4904722A (en) * 1985-04-08 1990-02-27 Exxon Research And Engineering Company Method for controlling viscosity of organic liquids and compositions thereof
US4927540A (en) * 1986-09-04 1990-05-22 The Dow Chemical Company Ionic complex for enhancing performance of water treatment membranes
US4969884A (en) * 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US5030216A (en) * 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5085775A (en) * 1990-12-05 1992-02-04 Allied-Signal Inc. Thin film composite ultrafiltration membrane
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5145584A (en) * 1990-12-05 1992-09-08 Allied-Signal Inc. Processes for using a thin film composite ultrafiltration membrane
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5180782A (en) * 1991-02-19 1993-01-19 Basf Corporation Compatible polyamide-acrylic compositions
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5474785A (en) * 1990-01-24 1995-12-12 Alza Corporation Delivery system comprising means for controlling internal pressure
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5540665A (en) * 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US5707663A (en) * 1993-05-28 1998-01-13 Alza Corporation Sustained antiepileptic therapy
WO2000023663A1 (en) 1998-10-21 2000-04-27 Reckitt Benckiser (Uk) Limited Dispensing device
US6060410A (en) * 1998-04-22 2000-05-09 Gillberg-Laforce; Gunilla Elsa Coating of a hydrophobic polymer substrate with a nonstoichiometric polyelectrolyte complex
WO2000062764A1 (en) 1999-04-20 2000-10-26 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
DE10003397A1 (en) * 2000-01-27 2001-08-09 Hartmann Paul Ag Polyelectrolyte solid system, process for producing the same and wound dressing
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US20020048600A1 (en) * 1998-11-02 2002-04-25 Padmanabh Bhatt Controlled delivery of active agents
US20020071863A1 (en) * 1999-12-09 2002-06-13 Dong Liang C. Antiviral medication
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US20030125714A1 (en) * 2001-12-18 2003-07-03 Edgren David Emil Dosage form for time-varying patterns of drug delivery
US20030198619A1 (en) * 2001-12-19 2003-10-23 Dong Liang C. Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20030224051A1 (en) * 2002-05-31 2003-12-04 Fink Tracy A. Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20030232082A1 (en) * 2001-09-28 2003-12-18 Shun-Por Li Modified release dosage forms
US20030232078A1 (en) * 2001-12-19 2003-12-18 Dong Liang C. Formulation & dosage form for the controlled delivery of therapeutic agents
US20040010000A1 (en) * 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
US20040091529A1 (en) * 2002-06-26 2004-05-13 David Edgren Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20040115262A1 (en) * 2002-07-29 2004-06-17 Frank Jao Formulations and dosage forms for controlled delivery of topiramate
US20040166160A1 (en) * 2003-01-14 2004-08-26 Ramkumar Subramanian Methods and dosage forms with modified viscosity layers
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US20040197407A1 (en) * 2003-02-11 2004-10-07 Ramkumar Subramanian Methods and dosage forms with modified layer geometry
US20050058707A1 (en) * 2003-08-06 2005-03-17 Iran Reyes Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
US20050069587A1 (en) * 2003-09-02 2005-03-31 Modi Nishit Bachulal Novel drug compositions and dosage forms of topiramate
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US20050129765A1 (en) * 2003-11-14 2005-06-16 Shaoling Li Controlled release of topiramate in liquid dosage forms
US20050136108A1 (en) * 2003-08-22 2005-06-23 Yam Noymi V. Stepwise delivery of topiramate over prolonged period of time
US20050148594A1 (en) * 2002-12-17 2005-07-07 Cink Russell D. Salts of fenofibric acid and pharmaceutical formulations thereof
US20050158365A1 (en) * 2003-12-22 2005-07-21 David Watson Drug delivery device with mechanical locking mechanism
US20050158382A1 (en) * 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
US20050169992A1 (en) * 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
US20050175690A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms
US20050175697A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms of topiramate
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050256194A1 (en) * 1998-09-10 2005-11-17 Bess William S Denaturants for sympathomimetic amine salts
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US20050276850A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Controlled release sodium valproate formulation
US20050287213A1 (en) * 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US20050287212A1 (en) * 2004-06-28 2005-12-29 Liang-Chang Dong Oral delivery system comprising a drug/polymer complex
US20050287214A1 (en) * 2004-06-28 2005-12-29 Ayer Atul D Squeeze controlled oral dosage form
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
US20060057206A1 (en) * 2004-08-19 2006-03-16 Wong Patrick S Controlled release nanoparticle active agent formulation dosage forms and methods
US20060067980A1 (en) * 2004-09-30 2006-03-30 Bausch & Lomb Incorporated Capsule for encasing tablets for surgical insertion into the human body
WO2006058022A1 (en) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060134196A1 (en) * 2002-12-17 2006-06-22 Abbott Gmbh & Co. Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US20060134162A1 (en) * 2004-12-16 2006-06-22 Larson Christopher W Methods for fabricating a drug delivery device
US20060165798A1 (en) * 2005-01-27 2006-07-27 Edgren David E Oral osmotic dosage form having a high flux membrane
US20060193877A1 (en) * 2005-02-28 2006-08-31 Pfab, Lp Compositions and methods of making sustained release liquid formulations
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
US20060257484A1 (en) * 2005-04-19 2006-11-16 Hwang Stephen S Combination of tramadol and substances that comprise gabapentin
WO2007053698A2 (en) 2005-10-31 2007-05-10 Alza Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
US20070281018A1 (en) * 2004-09-24 2007-12-06 Abbott Laboratories Sustained release formulations of opioid and nonopioid analgesics
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
EP1905435A2 (en) 2003-03-11 2008-04-02 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
WO2008084698A1 (en) 2006-12-28 2008-07-17 Astellas Pharma Inc. Tacrolimus sustained release pharmaceutical composition
US20080214629A1 (en) * 2007-02-09 2008-09-04 Scott Bull Controlled release compositions of tizanidine
US20090011027A1 (en) * 2007-05-30 2009-01-08 Neos Therapeutics, Lp Modifying Drug Release in Suspensions of Ionic Resin Systems
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20090162640A1 (en) * 2006-08-29 2009-06-25 Florida State University Research Foundation, Inc. Polymer mechanical damping composites and methods of production
EP2074992A1 (en) 2005-04-08 2009-07-01 Abbott Laboratories Pharmaceutical formulations
US20100041777A1 (en) * 2008-08-15 2010-02-18 Florida State University Research Foundation, Inc. Compacted polyelectrolyte complexes and articles
US7736668B2 (en) 1991-06-27 2010-06-15 Janssen Pharmaceutica Nv System for delaying drug delivery up to seven hours
US20100189782A1 (en) * 2007-03-02 2010-07-29 Gul Balwani Compositions Comprising Carisoprodol and Methods of Use Thereof
US7790061B2 (en) * 2003-06-17 2010-09-07 Board Of Trustees Of University Of Illinois Directed assembly of three-dimensional structures with micron-scale features
US20100260859A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Controlled-release clozapine compositions
WO2011122524A1 (en) 2010-03-29 2011-10-06 アステラス製薬株式会社 Controlled release pharmaceutical composition
US8226979B2 (en) 2003-09-26 2012-07-24 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
WO2014170755A2 (en) 2013-04-16 2014-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
WO2014179453A1 (en) 2013-04-30 2014-11-06 Abbvie, Inc. Methods for improving lipid profiles using atrasentan
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
EP2965753A1 (en) 2004-12-03 2016-01-13 Osmotica Kereskedelmi És Szolgáltató Kft Osmotic device containing amantadine and an osmotic salt
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2016132220A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release oral dosage form of gaba receptor agonist
WO2016134846A1 (en) 2015-02-27 2016-09-01 Rottapharm Ltd. Composition for the treatment of acne
WO2016166732A1 (en) 2015-04-17 2016-10-20 Murray And Poole Enterprises Limited Colchicine salicylate and uses thereof
WO2017008909A1 (en) 2015-07-16 2017-01-19 Rottapharm S. P. A. Oral formulation comprising berberine and morus alba extract
US9919280B2 (en) 2014-11-24 2018-03-20 The Florida State University Research Foundation, Inc. Method of forming polyelectrolyte complex capsules
US10064817B2 (en) 2004-11-24 2018-09-04 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US10087310B2 (en) 2013-03-15 2018-10-02 California Institute Of Technology Associative polymers and related compositions, methods and systems
US10119084B2 (en) 2015-09-18 2018-11-06 California Institute Of Technology Associative polymers to control formation of particulate matter from ignitable compositions and related compositions, methods and systems
US10206891B2 (en) 2012-11-02 2019-02-19 Murray And Poole Enterprises Ltd Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
US10253203B2 (en) 2014-02-04 2019-04-09 The Florida State University Research Foundation, Inc. Rough polyelectrolyte complex coatings and methods of forming
WO2019149884A1 (en) 2018-02-02 2019-08-08 Murray & Poole Enterprises, Ltd Use of colchicine to inhibit tumor growth and metastases
US10400186B2 (en) 2009-04-17 2019-09-03 California Institute Of Technology Associative polymers for mist-control
US10647953B2 (en) 2015-02-11 2020-05-12 The Florida State University Research Foundation, Inc. Surface treatment for cell culture
WO2021029429A1 (en) 2019-08-13 2021-02-18 大塚製薬株式会社 Oral pharmaceutical composition
WO2021089715A1 (en) 2019-11-06 2021-05-14 Murray And Poole Enterprises, Ltd. Use of colchicine in the treatment and prevention of lung cancer
WO2021252741A1 (en) 2020-06-10 2021-12-16 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
WO2023240186A1 (en) 2022-06-08 2023-12-14 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832746A (en) * 1953-02-18 1958-04-29 Du Pont Water-insoluble homogeneous polymer blends of a water-insoluble, waterdispersible, nonelectrolyte film-forming polymer with water-soluble linear organic polymers united by ionic crosslinkages, and their preparation, and fabrics coated therewith
US2832747A (en) * 1953-02-18 1958-04-29 Du Pont Polymeric compositions comprising linear polymers united through ionic crosslinkages and through covalent crosslinkages, process for their preparation, and fabrics coated therewith
US3041292A (en) * 1954-12-13 1962-06-26 Dow Chemical Co Composite ion exchange resin bodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832746A (en) * 1953-02-18 1958-04-29 Du Pont Water-insoluble homogeneous polymer blends of a water-insoluble, waterdispersible, nonelectrolyte film-forming polymer with water-soluble linear organic polymers united by ionic crosslinkages, and their preparation, and fabrics coated therewith
US2832747A (en) * 1953-02-18 1958-04-29 Du Pont Polymeric compositions comprising linear polymers united through ionic crosslinkages and through covalent crosslinkages, process for their preparation, and fabrics coated therewith
US3041292A (en) * 1954-12-13 1962-06-26 Dow Chemical Co Composite ion exchange resin bodies

Cited By (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737045A (en) * 1969-12-20 1973-06-05 Uivac Corp Membrane for use in dialysis and ultrafiltration and the production of such member
JPS6018698B2 (en) * 1971-07-02 1985-05-11 ロ−ン・プ−ラン・エス・ア Method for producing ionically crosslinked polymers
JPS5334887A (en) * 1971-07-02 1978-03-31 Rhone Poulenc Sa Process for preparing ionncrosslinked polymer
US3996318A (en) * 1972-12-21 1976-12-07 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Ten Behoeve Van Nijverheid, Handel En Verkeer Dynamic membrane
US3993616A (en) * 1974-08-05 1976-11-23 The Dow Chemical Company Alkali metal carboxylic polyelectrolyte solutions with N-methylol crosslinker
US4116545A (en) * 1976-10-27 1978-09-26 American Cyanamid Company Polymeric electrolyte for electrochromic display devices
FR2418252A1 (en) * 1978-02-27 1979-09-21 Ici Australia Ltd PROCESS FOR THE PRODUCTION OF AN AMPHOTERE RESIN OF IONIC EXCHANGE AND RESIN OBTAINED
US4439322A (en) * 1980-07-02 1984-03-27 Toray Industries, Inc. Polymethyl methacrylate membrane
US4377481A (en) * 1980-11-14 1983-03-22 Abcor, Inc. Blended, polymeric, matrix membrane and process of making and using same
US4511473A (en) * 1982-02-09 1985-04-16 Amf Incorporated Fibrous media containing millimicron-sized particulates
US4539373A (en) * 1982-07-12 1985-09-03 The Dow Chemical Company Thermoplastic polyelectrolyte complexes
US4511677A (en) * 1983-11-02 1985-04-16 Phillips Petroleum Company Ion exchange-active compositions consisting of water-soluble polyelectrolyte upon ion exchange functional substrate
US4516982A (en) * 1983-11-02 1985-05-14 Exxon Research And Engineering Co. Antimisting system for hydrocarbon fluids
US4737534A (en) * 1983-11-02 1988-04-12 Exxon Research And Engineering Company Method for controlling viscosity of organic liquids and compositions thereof
US4517333A (en) * 1983-12-12 1985-05-14 Exxon Research And Engineering Co. Novel viscosifiers for aqueous fluids based on polymer complexes
US4536539A (en) * 1983-12-12 1985-08-20 Exxon Research And Engineering Co. Dilatant behavior of interpolymer complexes in aqueous solution
US4489180A (en) * 1983-12-12 1984-12-18 Exxon Research And Engineering Co. Drag reduction agent utilizing water soluble interpolymer complexes
US4665115A (en) * 1984-08-22 1987-05-12 Exxon Research And Engineering Company Method for controlling viscosity of organic liquids and compositions
US4839203A (en) * 1985-04-03 1989-06-13 The Dow Chemical Company Semi-permeable membranes prepared via reaction of cationic groups with nucleophilic groups
US4704324A (en) * 1985-04-03 1987-11-03 The Dow Chemical Company Semi-permeable membranes prepared via reaction of cationic groups with nucleophilic groups
US4904722A (en) * 1985-04-08 1990-02-27 Exxon Research And Engineering Company Method for controlling viscosity of organic liquids and compositions thereof
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US4927540A (en) * 1986-09-04 1990-05-22 The Dow Chemical Company Ionic complex for enhancing performance of water treatment membranes
EP0285563A1 (en) 1987-04-02 1988-10-05 Ciba-Geigy Ag Transdermal therapeutic systems for combinations of active agents
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US4969884A (en) * 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5030216A (en) * 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5474785A (en) * 1990-01-24 1995-12-12 Alza Corporation Delivery system comprising means for controlling internal pressure
US5312389A (en) * 1990-10-29 1994-05-17 Felix Theeuwes Osmotically driven syringe with programmable agent delivery
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5085775A (en) * 1990-12-05 1992-02-04 Allied-Signal Inc. Thin film composite ultrafiltration membrane
US5145584A (en) * 1990-12-05 1992-09-08 Allied-Signal Inc. Processes for using a thin film composite ultrafiltration membrane
US5180782A (en) * 1991-02-19 1993-01-19 Basf Corporation Compatible polyamide-acrylic compositions
US7736668B2 (en) 1991-06-27 2010-06-15 Janssen Pharmaceutica Nv System for delaying drug delivery up to seven hours
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US20070009600A1 (en) * 1993-05-27 2007-01-11 Edgren David E Antidepressant dosage form
US8084059B2 (en) 1993-05-27 2011-12-27 Alza Corporation Antidepressant dosage form
US20040092601A1 (en) * 1993-05-27 2004-05-13 Edgren David Emil Antidepressant dosage form
US20040086570A1 (en) * 1993-05-27 2004-05-06 Edgren David Emil Antidepressant dosage form
US5980943A (en) * 1993-05-28 1999-11-09 Alza Corporation Sustained antiepileptic therapy
US5707663A (en) * 1993-05-28 1998-01-13 Alza Corporation Sustained antiepileptic therapy
US6287598B1 (en) 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5603954A (en) * 1994-01-18 1997-02-18 Alza Corporation Pentoxifylline therapy and method of use
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5540665A (en) * 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US6060410A (en) * 1998-04-22 2000-05-09 Gillberg-Laforce; Gunilla Elsa Coating of a hydrophobic polymer substrate with a nonstoichiometric polyelectrolyte complex
US20080181944A1 (en) * 1998-09-08 2008-07-31 Alza Corporation Dosage Form Comprising Therapeutic Formulation
US20090130204A1 (en) * 1998-09-08 2009-05-21 Encinal Pharmaceutical Investment Inc. Dosage Form Comprising Therapeutic Formulation
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US20100159002A1 (en) * 1998-09-08 2010-06-24 Liang-Chang Dong Dosage form comprising therapeutic formulation
US20030157163A1 (en) * 1998-09-08 2003-08-21 Liang-Chang Dong Dosage form comprising therapeutic formulation
US20070048368A1 (en) * 1998-09-09 2007-03-01 Alza Corporation Dosage form comprising liquid formulation
US7803401B2 (en) 1998-09-09 2010-09-28 Encinal Pharmaceutical Investments, Llc Dosage form comprising liquid formulation
US7147867B2 (en) 1998-09-09 2006-12-12 Alza Corporation Dosage form comprising liquid formulation
US20010001280A1 (en) * 1998-09-09 2001-05-17 Liang-Chang Dong Dosage form comprising liquid formulation
US20050256194A1 (en) * 1998-09-10 2005-11-17 Bess William S Denaturants for sympathomimetic amine salts
WO2000023663A1 (en) 1998-10-21 2000-04-27 Reckitt Benckiser (Uk) Limited Dispensing device
US6510561B1 (en) 1998-10-21 2003-01-28 Reckitt Benckiser (Uk) Limited Dispensing device
US20020048600A1 (en) * 1998-11-02 2002-04-25 Padmanabh Bhatt Controlled delivery of active agents
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
EP1652516A2 (en) 1998-11-02 2006-05-03 ALZA Corporation Osmotic controlled delivery of active agents
US6855334B2 (en) 1998-11-02 2005-02-15 Alta Corporation Controlled delivery of active agents
US6596314B2 (en) 1998-12-23 2003-07-22 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
WO2000062764A1 (en) 1999-04-20 2000-10-26 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US20020071863A1 (en) * 1999-12-09 2002-06-13 Dong Liang C. Antiviral medication
US6936746B2 (en) 2000-01-27 2005-08-30 Paul Hartmann Ag Polyelectrolyte solid system, method for the production thereof and a wound dressing
DE10003397A1 (en) * 2000-01-27 2001-08-09 Hartmann Paul Ag Polyelectrolyte solid system, process for producing the same and wound dressing
US20030232082A1 (en) * 2001-09-28 2003-12-18 Shun-Por Li Modified release dosage forms
US20070207204A1 (en) * 2001-12-18 2007-09-06 Alza Corporation Dosage Form for Time-Varying Patterns of Drug Delivery
US20030125714A1 (en) * 2001-12-18 2003-07-03 Edgren David Emil Dosage form for time-varying patterns of drug delivery
US20030198619A1 (en) * 2001-12-19 2003-10-23 Dong Liang C. Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20030232078A1 (en) * 2001-12-19 2003-12-18 Dong Liang C. Formulation & dosage form for the controlled delivery of therapeutic agents
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US20040010000A1 (en) * 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
US20030224051A1 (en) * 2002-05-31 2003-12-04 Fink Tracy A. Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20040091529A1 (en) * 2002-06-26 2004-05-13 David Edgren Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040115262A1 (en) * 2002-07-29 2004-06-17 Frank Jao Formulations and dosage forms for controlled delivery of topiramate
US20060134196A1 (en) * 2002-12-17 2006-06-22 Abbott Gmbh & Co. Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US20050148594A1 (en) * 2002-12-17 2005-07-07 Cink Russell D. Salts of fenofibric acid and pharmaceutical formulations thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20040166160A1 (en) * 2003-01-14 2004-08-26 Ramkumar Subramanian Methods and dosage forms with modified viscosity layers
US20040197407A1 (en) * 2003-02-11 2004-10-07 Ramkumar Subramanian Methods and dosage forms with modified layer geometry
EP1905435A2 (en) 2003-03-11 2008-04-02 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
US7790061B2 (en) * 2003-06-17 2010-09-07 Board Of Trustees Of University Of Illinois Directed assembly of three-dimensional structures with micron-scale features
US20050058707A1 (en) * 2003-08-06 2005-03-17 Iran Reyes Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
US20050136108A1 (en) * 2003-08-22 2005-06-23 Yam Noymi V. Stepwise delivery of topiramate over prolonged period of time
US20050069587A1 (en) * 2003-09-02 2005-03-31 Modi Nishit Bachulal Novel drug compositions and dosage forms of topiramate
US8226979B2 (en) 2003-09-26 2012-07-24 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US20050158382A1 (en) * 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
US8246986B2 (en) 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
US20050129765A1 (en) * 2003-11-14 2005-06-16 Shaoling Li Controlled release of topiramate in liquid dosage forms
US20050158365A1 (en) * 2003-12-22 2005-07-21 David Watson Drug delivery device with mechanical locking mechanism
US20050169992A1 (en) * 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
US20050175690A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms
US20050175697A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms of topiramate
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20080206337A1 (en) * 2004-03-05 2008-08-28 Hai Yong Huang Method of making dosage forms comprising polymeric compositions
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
US7713550B2 (en) 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US20050276850A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Controlled release sodium valproate formulation
US20050287213A1 (en) * 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US20050287212A1 (en) * 2004-06-28 2005-12-29 Liang-Chang Dong Oral delivery system comprising a drug/polymer complex
US20050287214A1 (en) * 2004-06-28 2005-12-29 Ayer Atul D Squeeze controlled oral dosage form
US20060057206A1 (en) * 2004-08-19 2006-03-16 Wong Patrick S Controlled release nanoparticle active agent formulation dosage forms and methods
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20070281018A1 (en) * 2004-09-24 2007-12-06 Abbott Laboratories Sustained release formulations of opioid and nonopioid analgesics
US20060067980A1 (en) * 2004-09-30 2006-03-30 Bausch & Lomb Incorporated Capsule for encasing tablets for surgical insertion into the human body
US8071073B2 (en) 2004-11-24 2011-12-06 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
EP2377557A2 (en) 2004-11-24 2011-10-19 MedPointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
EP2522365A1 (en) 2004-11-24 2012-11-14 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8518919B2 (en) 2004-11-24 2013-08-27 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
WO2006058022A1 (en) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US10064817B2 (en) 2004-11-24 2018-09-04 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US9919050B2 (en) 2004-11-24 2018-03-20 Meda Pharmaceuticals Inc. Compositions comprising azelastine
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
EP2486942A1 (en) 2004-11-24 2012-08-15 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
EP2965753A1 (en) 2004-12-03 2016-01-13 Osmotica Kereskedelmi És Szolgáltató Kft Osmotic device containing amantadine and an osmotic salt
US20060134162A1 (en) * 2004-12-16 2006-06-22 Larson Christopher W Methods for fabricating a drug delivery device
US20060165798A1 (en) * 2005-01-27 2006-07-27 Edgren David E Oral osmotic dosage form having a high flux membrane
US9522120B2 (en) 2005-02-28 2016-12-20 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US20060193877A1 (en) * 2005-02-28 2006-08-31 Pfab, Lp Compositions and methods of making sustained release liquid formulations
US20110237675A1 (en) * 2005-04-08 2011-09-29 Abbott Laboratories Pharmaceutical formulations
EP2074992A1 (en) 2005-04-08 2009-07-01 Abbott Laboratories Pharmaceutical formulations
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
US20060257484A1 (en) * 2005-04-19 2006-11-16 Hwang Stephen S Combination of tramadol and substances that comprise gabapentin
WO2007053698A2 (en) 2005-10-31 2007-05-10 Alza Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
US20090221621A1 (en) * 2005-10-31 2009-09-03 Alza Corporation Methods of Reducing Alcohol-Induced Dose Dumping for Opioid Sustained Release Oral Dosage Forms
US8206822B2 (en) 2006-08-29 2012-06-26 Florida State University Research Foundation, Inc. Polymer mechanical damping composites and methods of production
US8372891B2 (en) 2006-08-29 2013-02-12 Florida State University Research Foundation, Inc. Polymer mechanical damping composites and methods of production
US8206816B2 (en) 2006-08-29 2012-06-26 Florida State University Research Foundation, Inc. Polymer mechanical damping composites and methods of production
US20090162640A1 (en) * 2006-08-29 2009-06-25 Florida State University Research Foundation, Inc. Polymer mechanical damping composites and methods of production
US20100009148A1 (en) * 2006-08-29 2010-01-14 Florida State University Research Foundation, Inc. Polymer mechanical damping composites and methods of production
US8283030B1 (en) 2006-08-29 2012-10-09 Florida State University Research Foundation, Inc. Polymer mechanical damping composites and methods of production
WO2008084698A1 (en) 2006-12-28 2008-07-17 Astellas Pharma Inc. Tacrolimus sustained release pharmaceutical composition
US20090011018A1 (en) * 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
US8524749B2 (en) 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
US20080214629A1 (en) * 2007-02-09 2008-09-04 Scott Bull Controlled release compositions of tizanidine
US8895061B2 (en) 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US20100189782A1 (en) * 2007-03-02 2010-07-29 Gul Balwani Compositions Comprising Carisoprodol and Methods of Use Thereof
US20090011027A1 (en) * 2007-05-30 2009-01-08 Neos Therapeutics, Lp Modifying Drug Release in Suspensions of Ionic Resin Systems
US8313770B2 (en) 2007-05-30 2012-11-20 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US8314158B2 (en) 2008-08-15 2012-11-20 The Florida State University Research Foundation, Inc. Compacted polyelectrolyte complexes and articles
US20100041777A1 (en) * 2008-08-15 2010-02-18 Florida State University Research Foundation, Inc. Compacted polyelectrolyte complexes and articles
US8114918B2 (en) 2008-08-15 2012-02-14 The Florida State University Research Foundation, Inc. Compacted polyelectrolyte complexes and articles
US8222306B2 (en) 2008-08-15 2012-07-17 Florida State University Compacted polyelectrolyte complexes and articles
US20100260859A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Controlled-release clozapine compositions
US20100260858A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Drug delivery composition
US10400186B2 (en) 2009-04-17 2019-09-03 California Institute Of Technology Associative polymers for mist-control
WO2011122524A1 (en) 2010-03-29 2011-10-06 アステラス製薬株式会社 Controlled release pharmaceutical composition
US10842761B2 (en) 2012-11-02 2020-11-24 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US10206891B2 (en) 2012-11-02 2019-02-19 Murray And Poole Enterprises Ltd Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
US11944595B2 (en) 2012-11-02 2024-04-02 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US11944594B2 (en) 2012-11-02 2024-04-02 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US11666545B2 (en) 2012-11-02 2023-06-06 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US11026900B2 (en) 2012-11-02 2021-06-08 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US11026901B2 (en) 2012-11-02 2021-06-08 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US11026899B2 (en) 2012-11-02 2021-06-08 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US10842762B2 (en) 2012-11-02 2020-11-24 Murray And Poole Enterprises Ltd Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
US10265281B2 (en) 2012-11-02 2019-04-23 Murray And Poole Enterprises Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US10494509B2 (en) 2013-03-15 2019-12-03 California Institute Of Technology Associative polymers and related compositions, methods and systems
US10087310B2 (en) 2013-03-15 2018-10-02 California Institute Of Technology Associative polymers and related compositions, methods and systems
US10610488B2 (en) 2013-04-16 2020-04-07 Murray & Poole Enterprises, Ltd. Sustained-release formulations of colchicine and methods of using same
US10130585B2 (en) 2013-04-16 2018-11-20 Murray And Poole Enterprises Limited Methods of treating and/or preventing cardiovascular disease
US10105319B2 (en) 2013-04-16 2018-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
US11648206B2 (en) 2013-04-16 2023-05-16 Murray And Poole Enterprises Ltd Sustained-release formulations of colchicine and methods of using same
WO2014170755A2 (en) 2013-04-16 2014-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
WO2014179453A1 (en) 2013-04-30 2014-11-06 Abbvie, Inc. Methods for improving lipid profiles using atrasentan
US10253203B2 (en) 2014-02-04 2019-04-09 The Florida State University Research Foundation, Inc. Rough polyelectrolyte complex coatings and methods of forming
US9919280B2 (en) 2014-11-24 2018-03-20 The Florida State University Research Foundation, Inc. Method of forming polyelectrolyte complex capsules
US10647953B2 (en) 2015-02-11 2020-05-12 The Florida State University Research Foundation, Inc. Surface treatment for cell culture
WO2016132218A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of administering r-baclofen in an extended release dosage form
WO2016132220A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release oral dosage form of gaba receptor agonist
WO2016132217A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of improving gaba-b receptor agonist therapy
WO2016132233A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics
WO2016134846A1 (en) 2015-02-27 2016-09-01 Rottapharm Ltd. Composition for the treatment of acne
WO2016166732A1 (en) 2015-04-17 2016-10-20 Murray And Poole Enterprises Limited Colchicine salicylate and uses thereof
WO2017008909A1 (en) 2015-07-16 2017-01-19 Rottapharm S. P. A. Oral formulation comprising berberine and morus alba extract
US10428286B2 (en) 2015-09-18 2019-10-01 California Institute Of Technology Associative polymers for use in a flow and related compositions, methods and systems
US10119084B2 (en) 2015-09-18 2018-11-06 California Institute Of Technology Associative polymers to control formation of particulate matter from ignitable compositions and related compositions, methods and systems
WO2019149884A1 (en) 2018-02-02 2019-08-08 Murray & Poole Enterprises, Ltd Use of colchicine to inhibit tumor growth and metastases
WO2021029429A1 (en) 2019-08-13 2021-02-18 大塚製薬株式会社 Oral pharmaceutical composition
WO2021029430A1 (en) 2019-08-13 2021-02-18 大塚製薬株式会社 Oral pharmaceutical composition containing heterocyclic compound
WO2021089715A1 (en) 2019-11-06 2021-05-14 Murray And Poole Enterprises, Ltd. Use of colchicine in the treatment and prevention of lung cancer
US11311488B2 (en) 2020-06-10 2022-04-26 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
WO2021252741A1 (en) 2020-06-10 2021-12-16 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
WO2023240186A1 (en) 2022-06-08 2023-12-14 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Similar Documents

Publication Publication Date Title
US3546142A (en) Polyelectrolyte structures
US9636642B2 (en) Resilient anion exchange membranes prepared by polymerizing a composition
US4708981A (en) Water insoluble proton conducting polymers
EP0013677A1 (en) A fluid impermeable cation exchange membrane, process for its preparation, electrochemical cell comprising said membrane and an electrolytic process using said membrane
KR20140126199A (en) Manufacturing Method of Ion Exchange Membrane Using Porous Substrate and Polymer Coating
US2957206A (en) Production of ion selective permeable membrane and composition therefor
US2731408A (en) Electrically conductive membranes and the like comprising copolymers of divinyl benzene and olefinic carboxylic compounds
US3324068A (en) Plasticized polyelectrolyte gel and method of making same
KR101726658B1 (en) Vinylbenzene-styrene based anion exchange composite membranes with nitrile rubber and method for preparing the same
US3297595A (en) Semi-permeable membrane and production thereof
JP2005521771A (en) Polymer grafted support polymer
US10543463B2 (en) Homogeneous cation-exchange composite membrane having excellent chemical resistance and method for producing the same
KR101800857B1 (en) Vinylbenzyl-based and styrene-based anion exchange composite membrane having polyvinylidene fluoride and method of preparing thereof
US3004909A (en) Electropositive selective permeable membrane and method of production
KR101681637B1 (en) Styrene-tert-butyl styrene based cation exchange composite membranes with nitrile rubber and method for preparing the same
US3770666A (en) Vinyl alcohol copolymer ion exchange membranes
KR100447949B1 (en) Preparation of PVC/Polystyren base cation-exchange membrane
KR100473351B1 (en) Preparation method of Polyethylene/Polystyrene cation-exchange membrane
JPS582971B2 (en) Shinkiyo Ion Kokanmaku Oyobi Sonoseizouhouhou
KR101568861B1 (en) Manufacturing Method of Anion-Exchange Membrane
US3560424A (en) Shrink-proofing process
CN112546872B (en) Preparation method of monovalent selective cation exchange membrane
US3230273A (en) Selective membranes from rubber hydrochloride and chlorinated rubber
KR102357399B1 (en) A composition for mixed ion exchange polymers and bad odor removal method
KR101852061B1 (en) Vinylbenzene-styrene based anion exchange composite membranes with plasticizers and method for preparing the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: W.R. GRACE & CO., A CORP OF CT.

Free format text: MERGER;ASSIGNOR:AMICON CORPORATION;REEL/FRAME:004655/0480

Effective date: 19850911

AS Assignment

Owner name: W.R. GRACE & CO., A CORP. OF CT

Free format text: MERGER;ASSIGNOR:AMICON CORPORTION, A MASS. CORP.;REEL/FRAME:004704/0627